Page 126 - 《中国药房》2024年6期

Indian J Cancer，2013，50（4）：285-291. therapy-induced nausea and vomiting in patients receiving
[32] CHANG J H，CHEN G Y，WANG D，et al. Efficacy of cisplatin-based highly emetogenic chemotherapy：a
NEPA，a fixed antiemetic combination of netupitant and randomised，double-blind，placebo-controlled trial[J]. Lan‐
palonosetron，vs a 3-day aprepitant regimen for prevention cet Oncol，2009，10（6）：549-558.
of chemotherapy-induced nausea and vomiting（CINV）in [41] ISHIDO K，HIGUCHI K，AZUMA M，et al. Aprepitant，
Chinese patients receiving highly emetogenic chemo‐ granisetron，and dexamethasone versus palonosetron and
therapy（HEC）in a randomized phase 3 study[J]. Cancer dexamethasone for prophylaxis of cisplatin-induced nau‐
Med，2020，9（14）：5134-5142. sea and vomiting in patients with upper gastrointestinal
[33] 陈丽昆，程颖，张红雨，等. 阿瑞吡坦在中国肺癌患者中 cancer：a randomized crossover phase Ⅱ trial：KDOG
预防高剂量顺铂引起恶心和呕吐的疗效[J]. 中国新药与 1002[J]. Anticancer Drugs，2016，27（9）：884-890.
临床杂志，2015，34（10）：757-763. [42] WARR D G，HESKETH P J，GRALLA R J，et al. Efficacy
CHEN L K，CHENG Y，ZHANG H Y，et al. Efficacy of and tolerability of aprepitant for the prevention of
aprepitant in preventing high-dose cisplatin-induced nau‐ chemotherapy-induced nausea and vomiting in patients
sea and vomiting in Chinese patients with lung cancer[J]. with breast cancer after moderately emetogenic chemo‐
China Ind Econ，2015，34（10）：757-763. therapy[J]. J Clin Oncol，2005，23（12）：2822-2830.
[34] YANG L Q，SUN X C，QIN S K，et al. Efficacy and safety [43] 赵桂芳，熊杰，叶挺，等. 阿瑞匹坦预防阿霉素联合异环
of fosaprepitant in the prevention of nausea and vomiting 磷酰胺方案化疗后呕吐的临床观察[J]. 肿瘤学杂志，
following highly emetogenic chemotherapy in Chinese 2017，23（9）：802-806.
people：a randomized，double-blind，phase Ⅲ study[J]. ZHAO G F，XIONG J，YE T，et al. Clinical observation of
Eur J Cancer Care，2017，26（6）：e12668. aprepitant in the antiemetic treatment of doxorubicin and
[35] WENZELL C M，BERGER M J，BLAZER M A，et al. Pi‐ ifosfamide regimen induced vomiting[J]. J Chin Oncol，
lot study on the efficacy of an ondansetron-versus palono- 2017，23（9）：802-806.
setron-containing antiemetic regimen prior to highly [44] ZHANG L，LU S，FENG J，et al. A randomized phase Ⅲ
emetogenic chemotherapy[J]. Support Care Cancer，2013， study evaluating the efficacy of single-dose NEPA，a fixed
21（10）：2845-2851. antiemetic combination of netupitant and palonosetron，
[36] WEINSTEIN C，JORDAN K，GREEN S A，et al. Single- versus an aprepitant regimen for prevention of
dose fosaprepitant for the prevention of chemotherapy- chemotherapy-induced nausea and vomiting（CINV）in pa‐
induced nausea and vomiting associated with moderately tients receiving highly emetogenic chemotherapy（HEC）
emetogenic chemotherapy：results of a randomized， [J]. Ann Oncol，2018，29（2）：452-458.
double-blind phase Ⅲ trial[J]. Ann Oncol，2016，27（1）： [45] AAPRO M，RUGO H，ROSSI G，et al. A randomized
172-178. phase Ⅲ study evaluating the efficacy and safety of
[37] HESKETH P J，SCHNADIG I D，SCHWARTZBERG L NEPA，a fixed-dose combination of netupitant and palono‐
S，et al. Efficacy of the neurokinin-1 receptor antagonist setron，for prevention of chemotherapy-induced nausea
rolapitant in preventing nausea and vomiting in patients and vomiting following moderately emetogenic chemo‐
receiving carboplatin-based chemotherapy[J]. Cancer， therapy[J]. Ann Oncol，2014，25（7）：1328-1333.
2016，122（15）：2418-2425. [46] YEO W，LAU T K，KWOK C C，et al. NEPA efficacy and
[38] HESKETH P J，GRUNBERG S M，GRALLA R J，et al. tolerability during（neo）adjuvant breast cancer chemo‐
The oral neurokinin-1 antagonist aprepitant for the preven‐ therapy with cyclophosphamide and doxorubicin[J]. BMJ
tion of chemotherapy-induced nausea and vomiting：a mul‐ Support Palliat Care，2022，12（e2）：e264-e270.
tinational，randomized，double-blind，placebo-controlled [47] ARPORNWIRAT W，ALBERT I，HANSEN V L，et al.
trial in patients receiving high-dose cisplatin：the Aprepi‐ Phase 2 trial results with the novel neurokinin-1 receptor
tant Protocol 052 Study Group[J]. J Clin Oncol，2003，21 antagonist casopitant in combination with ondansetron
（22）：4112-4119. and dexamethasone for the prevention of chemotherapy-
[39] HERRSTEDT J，APORNWIRAT W，SHAHARYAR A，et induced nausea and vomiting in cancer patients receiving
al. Phase Ⅲ trial of casopitant，a novel neurokinin-1 recep‐ moderately emetogenic chemotherapy[J]. Cancer，2009，
tor antagonist，for the prevention of nausea and vomiting 115（24）：5807-5816.
in patients receiving moderately emetogenic chemotherapy [48] TAKAHASHI T，HOSHI E，TAKAGI M，et al. Multi‐
[J]. J Clin Oncol，2009，27（32）：5363-5369. center，phase Ⅱ，placebo-controlled，double-blind，rando-
[40] GRUNBERG S M，ROLSKI J，STRAUSZ J，et al. Effi‐ mized study of aprepitant in Japanese patients receiving
cacy and safety of casopitant mesylate，a neurokinin 1 high-dose cisplatin[J]. Cancer Sci，2010，101（11）：2455-
（NK1）-receptor antagonist，in prevention of chemo- 2461.

· 756 · China Pharmacy 2024 Vol. 35 No. 6 中国药房 2024年第35卷第6期